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Summary
The differential diagnosis between Burkitt lymphoma (BL) and diffuse large
B-cell lymphoma (DLBCL) can be challenging. BL has been reported to
express less BCL2 than DLBCL, but this issue has not been analysed sys-
tematically. BL expressing BCL2 can be considered to be MYC/BCL2 co-ex-
pressors, a feature that is associated with poorer outcome in DLBCL but
that has not been correlated with outcome in BL so far. We analysed the
expression of BCL2 in 150 cases of conventionally diagnosed BL using two
different BCL2 antibodies. BCL2 expression was detected in 23% of the
cases, though the expression varied in intensity and number of positive
cells. We did not detect any relevant differences in clinical presentation and
outcome between BCL2-positive and BCL2-negative BL in a subgroup of
43 cases for which detailed clinical data were available. An independent
cohort of 17 BL with expression of BCL2 were analysed molecularly, with
13 of 17 cases classified as molecularly defined BL (Burkitt Lymphoma)
using gene expression profiling on formalin-fixed paraffin-embedded tis-
sues. The four lymphomas diagnosed molecularly as intermediates did not
differ in clinical presentation and outcome from molecularly defined BL.
Keywords: NanoString, nCounter, classifier, Burkitt, diffuse large B-cell
lymphoma, MYC.
The differential diagnosis of Burkitt lymphoma (BL) versus
diffuse large B-cell lymphoma (DLBCL) can be challenging.
In daily practice, the diagnosis of BL and DLBCL is based on
morphological assessment, immunophenotype and detection
of MYC translocations and absence of translocations involv-
ing the BCL2 or BCL6 genes by fluorescence in situ
hybridization (FISH) (conventionally diagnosed BL). The
immunophenotype, which is assessed to distinguish BL from
DLBCL, frequently includes BCL2 expression (Cogliatti et al,
2006; Kluin & Schuuring, 2011; Salaverria & Siebert, 2011).
The former World Health Organization (WHO) classification
stated that BCL2 is not expressed in BL (Jaffe et al, 2001).
However, gene expression profiling identified cases of molec-
ularly defined BL (mBL) with BCL2 expression not caused
by translocations of the gene (Dave et al, 2006; Hummel
et al, 2006). These findings led to a new weighting of the
immunophenotypic features of BL in the current WHO clas-
sification, which describes BCL2 as being expressed in up to
20% of BL cases, predominantly with a weak expression pat-
tern (Swerdlow et al, 2008).
BL expressing BCL2 must be distinguished from the group
of lymphomas called ‘B-cell lymphomas unclassified with fea-
tures intermediate between BL and DLBCL’ (conventionally
diagnosed intermediates), which comprises a heterogeneous
group of lymphomas. Conventionally diagnosed intermediate
lymphomas show at least some features reminiscent of BL,
such as a monomorphic cytological picture with small- to
medium-sized blasts, a starry sky pattern, high proliferation
and frequently translocations involving the MYC gene (Swerd-
low et al, 2008). However, conventionally diagnosed interme-
diate lymphomas often display immunophenotypic features,
such as strong BCL2, expression or genetic features like BCL2
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or BCL6 gene translocations that preclude a BL diagnosis. The
presence of both MYC and BCL2 or BCL6 translocations is
called ‘double hit’ and is usually not compatible with the diag-
nosis of BL (Boerma et al, 2009; Aukema et al, 2011, 2014).
Intermediate lymphomas can also be identified by gene
expression profiling independent of morphology, immunophe-
notype and FISH data. Gene expression profiling-based
molecular intermediates (m-intermediates) are classified as
conventionally diagnosed BL or DLBCL by conventional diag-
nostics. A subgroup of m-intermediates lack a genetic ‘double
hit’ constellation (Hummel et al, 2006). Translocations of
BCL6 and BCL2, and thus ‘double hit’ lymphomas, are exceed-
ingly rare in children and adolescents, but m-intermediates in
the young age group can be detected by gene expression profil-
ing (Klapper et al, 2008). Similar to ‘double hit’ lymphomas,
m-intermediates identified by gene expression profiling occa-
sionally express BCL2 protein (Klapper et al, 2008). Currently,
gene expression profiling is not available for routine diagnosis,
thus for diagnostic pathologists it is currently unclear whether
strong expression of BCL2 justifies the classification of a case
with the morphological and immunophenotypical features of a
BL as an intermediate lymphoma.
In DLBCL, not only the genetic ‘double hit’ with MYC
and BCL2 translocations but also the co-expression of both
MYC and BCL2 proteins (‘co-expressor’) characterize a sub-
group of DLBCL with an aggressive course (Johnson et al,
2009; Green et al, 2012; Horn et al, 2013; Hu et al, 2013;
Perry et al, 2014). In BL, high levels of MYC protein expres-
sion are due to MYC translocations (Hummel et al, 2006).
Whether the co-expression with BCL2 indicates inferior out-
come in BL has not yet been studied.
To gain a better understanding of the clinical implications,
we systematically analysed BCL2 expression in BL. To this end,
we screened a large cohort of conventionally diagnosed BL for
BCL2 expression using two antibodies that detect BCL2. We
correlated the BCL2 expression status with the clinical course
in cases with available clinical data. Moreover, we applied
digital multiplexed gene expression profiling on formalin-
fixed paraffin-embedded (FFPE) tissue specimens from BCL2-
positive and BCL2-negative conventionally diagnosed BL cases
to determine whether they should be classified as mBL.
Patients and methods
Patients and tissue specimens
BL cases from all age groups that were diagnosed between
2001 and 2014 were identified within the files of the Lymph
Node Registry Kiel. Cases with sufficient FFPE tissue were
arranged in a tissue microarray (TMA) with duplicate cores
06 mm in diameter for each lymphoma. We included only
lymphomas with morphological features compatible with the
diagnosis of conventionally diagnosed BL as judged on full
tissue sections. The lymphomas were composed of dense
sheets of monomorphic small- to medium-sized blasts with a
narrow rim of cytoplasm showing cohesive growth and a
starry sky pattern in areas of good tissue preservation. The
TMA cohort comprised a total of 150 cases of conventionally
diagnosed BL from all age groups. A subgroup of cases with
specimens of sufficient size and a tumour content of at least
70% were selected for molecular analysis (n = 17). Clinical
data were available for 43 cases.
Immunohistochemistry and fluorescence in situ
hybridization (FISH)
Analysis of BCL2 expression was conducted using clone 100/
D5 (DAKO, Glostrup, Denmark) or clone E17 (Zytomed, Ber-
lin, Germany) (Adam et al, 2013). Analysis of CD20, CD10
and Ki67 was performed using an automated stainer (Leica,
Wetzlar, Germany). BCL2 immunohistochemistry results were
scored by visual inspection in the following categories: negative
(no staining in lymphoma cells), 1–25% positive lymphoma
cells, 26–50% positive lymphoma cells, 51–75% positive lym-
phoma cells and >75% positive lymphoma cells. The intensity
of BCL2 staining was analysed relative to non-neoplastic
T-cells serving as an internal control as weak (weaker than
T-cells) or strong (stronger or equal to T-cells). Staining inten-
sity of T-cells also served as a control for immunoreactivity of
the tissue. The Ki67 index was assessed in 5% steps, whereas
CD20, CD10 and TdT were reported as positive or negative.
FISH was conducted as recently described (Ventura et al,
2006). Break-apart probes for the MYC, BCL2and BCL6 loci as
well as IGH-MYC and IGH-BCL2 fusion probes were applied
(Abbott, Abbott Park, Illinois, USA) (Barth et al, 2013).
RNA extraction and digital multiplexed gene expression
Formalin-fixed paraffin-embedded material was cut into five
10 lm-thick sections per sample. RNA was extracted accord-
ing to the manufacturer’s instructions (ExpressArt FFPE
Clear RNAready Kit, AmpTec, Hamburg, Germany), quanti-
fied and checked for quality (Agilent RNA 6000 Nano Chips,
Agilent Technologies, Santa Clara, CA, USA) as previously
described (Masque-Soler et al, 2013). Gene expression analy-
sis was performed using nCounter/Nanostring technology
following the previously published protocol (Masque-Soler
et al, 2013). In five specimens with previously visualized
BCL2 expression pattern on FFPE sections, BCL2-positive
and -negative areas were analogously labelled on unstained
tissue sections, manually dissected and separately processed
for RNA extraction and gene expression.
Results
Incidence of BCL2 expression in conventionally diagnosed
BL
We analysed 150 cases of conventionally diagnosed BL diag-
nosed by morphological and immunophenotypical features
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as well as the presence of MYC translocations. All cases were
positive for CD20, CD10 and negative for TdT with a Ki67
index above 90%. All of the samples tested harboured MYC
(150/150, 100%) translocations but lacked BCL2 (0/141, 0%)
or BCL6 (0/137, 0%) translocations by FISH. TMAs contain-
ing our case cohort were stained by two antibodies directed
against BCL2. Applying the most widely used antibody clone,
100/D5, 146 cases yielded an interpretable result. No expres-
sion was detected in 113/146 cases (77%). BCL2 expression
was detected at various levels in 33/146 (23%) of the cases
with interpretable results [1–25% positive lymphoma cells in
16/146 (11%), 26–50% in 6/146 (4%), 51–75% in 6/146
(4%) and >75% in 5/146 (3%)]. The expression intensity
was weak (weaker than non-neoplastic T-cells as internal
controls) in the majority of cases (Fig 1) and only two cases
showed strong staining intensity equal to or stronger than
non-neoplastic T-cells (data not shown). To analyse whether
BCL2 protein expression might escape detection by the fre-
quently used antibody clone 100/D5, as reported for follicu-
lar lymphoma (Adam et al, 2013), the cases were additionally
analysed by the antibody clone E17. However, none of the
conventionally diagnosed BL that lacked BCL2 expression
using the clone 100/D5 stained positive with the clone E17
(0/104 of cases with interpretable results, Table S1).
Pathological features of conventionally diagnosed BL
showing expression of BCL2
A subgroup of 17 patients with conventionally diagnosed BL
was further studied on full tissue sections (seven of these
patients were also part of the TMA cohort). The patients’
clinical features were typical for BL and they were predomi-
nantly young (median age 11 years, range 3–24 years) and
male (Table I). All but one patient presented with lym-
phomas with no or limited bone marrow infiltration and
they were frequently at a limited stage (Table I). The lym-
phomas manifested predominantly at extranodal sites with
10/17 in the small or large intestine or as an abdominal or
ileocecal mass (Table I).
Histopathology and genetics were compatible with the
diagnosis of conventionally diagnosed BL, with small to
medium-sized blasts with a narrow rim of cytoplasm. A
starry sky pattern was detectable in the majority of cases, at
least in areas with good tissue preservation. A plasmacytic
differentiation was not detectable. All lymphomas displayed
the conventionally diagnosed BL immunophenotype with
expression of CD20 and CD10, high proliferation as mea-
sured by the Ki67 index and absence of TdT expression
(Table I). Only 1/8 cases (13%) was positive for Epstein-Barr
virus (EBV) by EBV-encoded small RNA (EBER) in situ
hybridization (data not shown). The genetic features were
compatible with the diagnosis in conventionally diagnosed
BL (Table I). The BCL2-expressing cells were either diffusely
dispersed over the whole lymphoma/tumour or clustered in
restricted areas while leaving other areas BCL2-negative
(Fig 2). In cases with spatially divergent BCL2 expression,
the phenotype and the morphology did not differ between
BCL2-positive and BCL2-negative areas of the lymphoma
(Fig 2). Spatially divergent BCL2 expression occurred in 23%
of the BCL2 positive cases.
BCL2-positive conventionally diagnosed BL show a
molecular profile of mBL or m-intermediate
In order to understand whether the expression of BCL2 in
conventionally diagnosed BL truly is a BL, we performed a
gene expression analysis using RNA obtained from FFPE tis-
sues and digital multiplexed gene expression technology, as
previously published (Masque-Soler et al, 2013). Thirteen of
17 conventionally diagnosed BL (76%) were classified as
mBL, confirming the clinicopathological-cytogenetic diagno-
sis (Table I). In five specimens the BCL2-positive and nega-
tive areas of the conventionally diagnosed BL were manually
(A)
(B)
Fig 1. Variable expression of BCL2 in BL. Scattered cells comprising
about 10% of all lymphoma cells (A, corresponding to Case 9 in
Table I) and diffusely dispersed BCL2-positive lymphoma cells com-
prising about 40% (B, corresponding to Case 12 in Table I). Insets
show high magnifications with arrowheads indicating non-neoplastic
T-cells and arrows indicating BCL2-positive lymphoma cells. Original
magnification 400x.
Burkitt Lymphoma Showing Expression of BCL2
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dissected and analysed separately for gene expression. All of
these were classified as mBL in both the BCL2-negative and
the BCL2-positive areas of the tumour (cases 1, 2, 3, 4 and
11 in Table I).
Interestingly, 4/17 conventionally diagnosed BL (24%)
were classified as lymphomas intermediate between mBL and
non-mBL (m-intermediate, cases 5, 6, 13 and 16 in Table I,
Fig 3). All m-intermediate lymphomas showed typical fea-
tures of conventionally diagnosed BL. The patients were
under the age of 16 and 3 patients presented with an abdom-
inal mass (Table I). Although the morphology of these lym-
phomas was ambiguous due to poor tissue quality (Fig 3),
all lymphomas were positive for t(8;14) and lacked BCL6
breaks. There were no BCL2 breaks in two cases with avail-
able data. The patients were treated according to the proto-
cols for BL and did not suffer a relapse.
BCL2 expression in paediatric conventionally diagnosed
BL is not associated with unfavourable outcome
The co-expression of BCL2 and MYC is associated with poorer
outcome in DLBCL. In our cohort of 13 mBL, based on gene
expression profiles and available clinical data, the outcome
was excellent and none of the patients for whom a molecular
diagnosis was available in the current study showed a relapse
(Table I). We thus analysed a larger number of conventionally
diagnosed BL treated according to protocols of the Berlin-
Frankf€urt-M€unster Non-Hodgkin lymphoma (BFM-NHL)
study group. Forty-three patients for whom BCL2 expression
status based on whole tissue section staining was available
(including three patients that were analysed by gene expression
profiling), were registered in the BFM-NHL database, thus
providing us with complete clinical data. Seventeen of 43 cases
of conventionally diagnosed BL (40%) were reported to show
BCL2 expression. There was no major difference in clinical
variables between the group with and the group without
known BCL2 expression status, with the exception that a lower
(A)
(B) (C)
(D)
(F) (G) (H) (I) (J) (K)
(E)
Fig 2. Example of a case of BL with differential spatial expression of
BCL2. The specimen was obtained from an ileocecal mass in a 12-
year-old male child (Case 1 in Table I). The tumour displays hetero-
geneous expression of BCL2 (A, overview; B and C high magnifica-
tion). Both areas with and without BCL2 expression show the typical
morphology and immunophenotype of BL. BCL2-positive areas: B,
BCL2, D, haematoxylin and eosin, F, CD20, G, CD10, H, Ki67.
BCL2-negative areas: C, BCL2, E, haematoxylin and eosin, I, CD20,
J, CD10, K, Ki67. Original magnification 100x in A and 400x in B-K.
(A)
(B)
Fig 3. Two lymphomas diagnosed as BL by means of morphology,
immunophenotype and genetics that were classified as intermediate
BL by gene expression profiling. Panel A corresponds to Case 5 in
Table I; panel B corresponds to Case 16 in Table I. All panels are
stained with haematoxylin and eosin. Original magnification 200x.
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number of cases with known BCL2-expression status had bone
marrow involvement and elevated lactate dehydrogenase
(LDH) levels (Table SII). A comparison of the clinical vari-
ables, gender, age, stage, bone marrow involvement, central
nervous system involvement, lactate dehydrogenase level,
B-symptoms, risk groups and event-free survival did not reveal
any difference between 26 BCL2-negative and 17 BCL2-posi-
tive cases of conventionally diagnosed BL (Table II).
Discussion
BCL2 is a member of the BCL2 family of proteins, which are
involved in a variety of cellular processes and predominantly
act in an anti-apoptotic manner (Siddiqui et al, 2015). BCL2
is a promising therapeutic target in lymphomas that express
the protein (Johnson-Farley et al, 2015). In this study we
showed that BCL2 is expressed in a considerable number of
conventionally diagnosed BL cases. The percentage of BCL2-
positive conventionally diagnosed BL cases in the BFM-NHL
database (39%) was higher than the percentage of conven-
tionally diagnosed BL reported as positive in our tissue
microarray study (23%). The difference might be due to the
fact that full slides were analysed for BCL2 expression for the
BFM-NHL data, which allows areas of local BCL2 reactivity
to be detected that might escape identification using a TMA.
Translocations involving BCL2 as a cause of BCL2 expression
were ruled out in our study, confirming previous data (Dave
et al, 2006; Hummel et al, 2006; Klapper et al, 2008).
Whether other genetic aberrations, such as mutations in the
promoter region or epigenetic mechanisms in BCL2-positive
subclones of conventionally diagnosed BL, cause the protein’s
expression has not yet been elucidated. It is worth mention-
ing that the widely used antibody clone 100/D5 (DAKO,
Glostrup, Denmark) is sufficiently sensitive to identify BCL2
expression in conventionally diagnosed BL. In contrast to
follicular lymphoma (Adam et al, 2013), mutations of BCL2
epitopes do not seem to influence immunoreactivity despite
the fact that mutations in BCL2 occasionally occur in
conventionally diagnosed BL (Love et al, 2012). It is impor-
tant to mention that BCL2 staining suffers from a high
inter-observer variability (de Jong et al, 2007).
The expression of BCL2 is associated with poorer survival
in DLBCL, especially if co-expressed with MYC protein
(Horn et al, 2013; Perry et al, 2014). As all BL cases express
high levels of MYC (Dave et al, 2006; Hummel et al, 2006),
the BCL2-positive BL are MYC and BCL2 co-expressors. Our
findings show that, in conventionally diagnosed BL or mBL,
co-expression of MYC and BCL2 is not associated with a
poorer outcome. Certainly, the differences in therapeutic
protocols might explain the different prognostic impact of
MYC-BCL2 co-expression. All conventionally diagnosed BL
and mBL cases in our study were paediatric patients who
received intensive chemotherapy according to paediatric pro-
tocols. The DLBCL for which the negative prognostic impact
of MYC-BCL2 co-expression has been demonstrated were
mainly treated with less aggressive immunochemotherapy
using a CHOP [cyclophosphamide, hydroxydaunorubicin
(doxorubicin), vincristine, prednisolone]-based regimen
(Zhou et al, 2014). Whether intensified chemotherapy might
overcome the negative prognostic impact of MYC-BCL2 co-
expression in DLBCL is still uncertain. It is noteworthy that
a recent study of a young, high-risk cohort of DLBCL treated
with intensified immunochemotherapy identified biological
risk factors that differ from cohorts of elderly patients with
DLBCL (Horn et al, 2015).
Using our recently developed gene expression-based classi-
fier (Masque-Soler et al, 2013), we were able to apply nanos-
tring technology to manually dissected areas of the
lymphoma. BCL2-positive and BCL2-negative areas of the
same lymphomas were independently and consistently classi-
fied as mBL, implying that the expression of BCL2 does not
indicate a ‘transformation’ of BL towards an intermediate
lymphoma. To our knowledge, this is the first example of
gene expression-based molecular diagnosis in independently
analysed areas of a lymphoma. The consistency of the results
Table II. Characteristics BCL2-positive and -negative BL patients fol-
lowed by the BFM-NHL study group.
Characteristic
BCL2 negative
(n = 26)
BCL2 positive
(n = 17)
P value
(Chi)
Gender
Male 24 92% 15 88%
Female 2 8% 2 12% 100
Age (years)
<10 13 50% 9 53%
10–14 9 35% 3 18%
>14 4 15% 5 29% 039
Stage of disease
I 1 5% 0 0%
II 5 24% 5 33%
III 12 57% 8 53%
IV 1 5% 0 0%
B-AL 2 10% 2 13% 096
BM involvement
Yes 2 8% 2 12% 100
CNS involvement
Yes 2 8% 1 6% 100
LDH (iu/l)
<500 15 63% 10 59%
500–1000 6 25% 3 18%
>1000 3 13% 4 24% 074
B symptoms
Yes 8 31% 3 18% 048
Risk group
R1 0 0% 0 0%
R2 13 62% 9 60%
R3 3 14% 2 13%
R4 5 24% 4 27% 100
Event-free survival 96  4% 82  9% 015 LR
B-AL, Burkitt-acute leukaemia; BM, bone marrow; CNS, central ner-
vous system; LDH, lactate dehydrogenase; LR, likelihood ratio.
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confirms the reliability of our multiplex assay and suggests
that the molecular diagnosis based on our classifier is not
influenced by intratumoural heterogeneity.
We have previously shown that m-intermediates in children
do not harbour a genetic ‘double hit’ constellation and show
more ‘Burkitt-ness’ than adult m-intermediates (Klapper et al,
2008; Salaverria & Siebert, 2011). This suggests that the major-
ity of m-intermediates in children and young adults are, in fact,
BL, which escape classification as mBL due to minor divergence
of gene expression or simply the choice of the statistical cut-off
in the current algorithms (Klapper et al, 2008). This study
again identified four m-intermediates among 17 lymphomas
that were classified as conventionally diagnosed BL on the basis
of morphology and immunophenotype. However, the clinical,
pathological and genetic features of the m-intermediates, such
as age, localization, site of the lymphoma, morphology,
immunophenotype, cytogenetics and outcome, do not differ
from mBL in this cohort of children and young adults. This
finding raises questions as to the potential advantage of molec-
ular over conventional diagnosis for mature aggressive B-cell
lymphomas in children and adolescents. Obviously, m-inter-
mediates in young patients do not present a clinically or bio-
logically relevant subgroup. As our cohort of molecularly
classified lymphomas is rather small, molecular diagnosis based
on gene expression profiling needs to be evaluated in larger
cohorts of lymphomas in children and young adults to under-
stand its value as a diagnostic and prognostic tool.
Our data suggest that BCL2 expression is a feature
detected to a variable extent in a considerable number of
cases of BL. It is important to mention, that even a high
expression intensity or a high number of BCL2 positive lym-
phoma cells does not preclude the diagnosis of BL if all other
features are compatible with this diagnosis, especially if BCL2
translocations are absent. BCL2 expression in a lymphoma
that clinically, morphologically, immunophenotypically and
genetically resembles BL is not sufficient to diagnose an
intermediate lymphoma, especially if the BCL2 expression is
developed only in a subgroup of lymphoma cells (as was the
case in most of the specimens analysed in this study).
In summary, more than 20% of lymphomas with the clin-
ical, morphological, immunophenotypical and genetic fea-
tures of conventionally diagnosed BL express BCL2. This
expression is variable in extent and can occur diffusely or be
restricted to certain areas of the lymphoma. BCL2 expression
in conventionally diagnosed BL is almost always weaker than
in non-neoplastic T-cells. Molecular diagnosis of BCL2-posi-
tive conventionally diagnosed BL confirms the diagnosis in
the vast majority of cases. The clinical significance of m-in-
termediates in children is uncertain at the current time.
BCL2 expression in conventionally diagnosed BL is not asso-
ciated with poorer outcome in paediatric patients. Diagnostic
pathologists must be aware of the BCL2 expression pattern
in conventionally diagnosed BL.
Acknowledgements
The authors would like to thank Olivera Batic, Dana Germer,
Charlotte Botz-von Drathen, Claudia Becher, Reina Z€uhlke-
Jenisch and Dorit Schuster for their excellent technical support
and Kay Dege for editing the manuscript. This work was sup-
ported by a grant from the German Cancer Aid (1090547), the
KinderKrebsInitiative (KKI) Buchholz/Holm-Seppensen, an
intramural grant of the Medical Faculty of the University of
Kiel to WK (grant number F343911), and the e:BIO project
MMML-MYC-SYS and e:MED (MMML-Demonstrators) both
funded by the German Ministry of Science and Education
(BMBF grant number 0316166 and 031A428D, respectively).
S.M.A is a fellow of the JSM-UMCG MD-PhD program and a
recipient of the ‘Nijbakker-Morra’ and ‘Hippocrates’ Founda-
tions awards and is supported by ‘Foundation de Drie Lichten,
Leiden, The Netherlands’, the ‘Rene Vogels’ Foundation’ and
in the framework of a “JSM-Ubbo Emmius Foundation Talent
Grant “.
Author contributions
NMS and MS performed DMGE analysis, CK and RS per-
formed bioinformatic analysis, IN, SMA and RSie analysed
genetic data and interpreted results. BB provided clinical data
and performed statistical tests. WK designed the research,
provided funding and wrote the manuscript. All authors have
approved the final version of the manuscript.
Conflict of interest
The authors have no conflict of interest to disclose.
Supporting Information
Additional Supporting Information may be found in the
online version of this article:
Table S1. BCL2 expression for n = 134 BL in the TMA
cohort for which an interpretable result was available for
both BCL2 antibodies used in the study.
Table S2. Patient characteristics of patients with versus
patients without known BCL2 status.
References
Adam, P., Baumann, R., Schmidt, J., Bettio, S.,
Weisel, K., Bonzheim, I., Fend, F. & Quin-
tanilla-Martinez, L. (2013) The BCL2 E17 and
SP66 antibodies discriminate 2 immunopheno-
typically and genetically distinct subgroups of
conventionally BCL2-”negative” grade 1/2 follic-
ular lymphomas. Human Pathology, 44, 1817–
1826.
Aukema, S.M., Siebert, R., Schuuring, E., van Imh-
off, G.W., Kluin-Nelemans, H.C., Boerma, E.J.
& Kluin, P.M. (2011) Double-hit B-cell lym-
phomas. Blood, 117, 2319–2331.
Aukema, S.M., Kreuz, M., Kohler, C.W., Roso-
lowski, M., Hasenclever, D., Hummel, M., Kup-
pers, R., Lenze, D., Ott, G., Pott, C., Richter, J.,
Rosenwald, A., Szczepanowski, M., Schwaenen,
Burkitt Lymphoma Showing Expression of BCL2
ª 2015 John Wiley & Sons Ltd, British Journal of Haematology 7
C., Stein, H., Trautmann, H., Wessendorf, S.,
Trumper, L., Loeffler, M., Spang, R., Kluin,
P.M., Klapper, W. & Siebert, R. (2014) Biologi-
cal characterization of adult MYC-translocation-
positive mature B-cell lymphomas other than
molecular Burkitt lymphoma. Haematologica,
99, 726–735.
Barth, T.F., Flossbach, L., Bernd, H.W., Bob, R.,
Buck, M., Cogliatti, S.B., Feller, A.C., Hans-
mann, M.L., Hartmann, S., Horn, H., Klapper,
W., Kradolfer, D., Mattfeldt, T., Moller, P.,
Rosenwald, A., Stein, H., Thorns, C. & Ott, G.
(2013) Round robin test for detection of geno-
mic aberrations in non-Hodgkin lymphoma by
in situ hybridization. Der Pathologe, 34, 329–
334.
Boerma, E.G., Siebert, R., Kluin, P.M. & Baudis,
M. (2009) Translocations involving 8q24 in Bur-
kitt lymphoma and other malignant lymphomas:
a historical review of cytogenetics in the light of
todays knowledge. Leukemia, 23, 225–234.
Cogliatti, S.B., Novak, U., Henz, S., Schmid, U.,
Moller, P. & Barth, T.F. (2006) Diagnosis of
Burkitt lymphoma in due time: a practical
approach. British Journal of Haematology, 134,
294–301.
Dave, S.S., Fu, K., Wright, G.W., Lam, L.T., Kluin,
P., Boerma, E.J., Greiner, T.C., Weisenburger,
D.D., Rosenwald, A., Ott, G., Muller-Hermelink,
H.K., Gascoyne, R.D., Delabie, J., Rimsza, L.M.,
Braziel, R.M., Grogan, T.M., Campo, E., Jaffe,
E.S., Dave, B.J., Sanger, W., Bast, M., Vose,
J.M., Armitage, J.O., Connors, J.M., Smeland,
E.B., Kvaloy, S., Holte, H., Fisher, R.I., Miller,
T.P., Montserrat, E., Wilson, W.H., Bahl, M.,
Zhao, H., Yang, L., Powell, J., Simon, R., Chan,
W.C. & Staudt, L.M. (2006) Molecular diagnosis
of Burkitt’s lymphoma. New England Journal of
Medicine, 354, 2431–2442.
Green, T.M., Young, K.H., Visco, C., Xu-Monette,
Z.Y., Orazi, A., Go, R.S., Nielsen, O., Gadeberg,
O.V., Mourits-Andersen, T., Frederiksen, M.,
Pedersen, L.M. & Moller, M.B. (2012) Immuno-
histochemical double-hit score is a strong pre-
dictor of outcome in patients with diffuse large
B-cell lymphoma treated with rituximab plus
cyclophosphamide, doxorubicin, vincristine, and
prednisone. Journal of Clinical Oncology, 30,
3460–3467.
Horn, H., Ziepert, M., Becher, C., Barth, T.F.,
Bernd, H.W., Feller, A.C., Klapper, W., Hum-
mel, M., Stein, H., Hansmann, M.L., Schmelter,
C., Moller, P., Cogliatti, S., Pfreundschuh, M.,
Schmitz, N., Trumper, L., Siebert, R., Loeffler,
M., Rosenwald, A. & Ott, G. (2013) MYC status
in concert with BCL2 and BCL6 expression pre-
dicts outcome in diffuse large B-cell lymphoma.
Blood, 121, 2253–2263.
Horn, H., Ziepert, M., Wartenberg, M., Staiger,
A.M., Barth, T.F., Bernd, H.W., Feller, A.C.,
Klapper, W., Stuhlmann-Laeisz, C., Hummel,
M., Stein, H., Lenze, D., Hartmann, S., Hans-
mann, M.L., M€oller, P., Cogliatti, S., Pfreund-
schuh, M., Tr€umper, L., Loeffler, M., Glass, B.,
Schmitz, N., Ott, G. & Rosenwald, A. (2015)
Different biological risk factors in young poor-
prognosis and elderly patients with diffuse large
B-cell lymphoma. Leukemia, Feb 17. doi:
10.1038/leu.2015.43. [Epub ahead of print]
Hu, S., Xu-Monette, Z.Y., Tzankov, A., Green, T.,
Wu, L., Balasubramanyam, A., Liu, W.M., Visco,
C., Li, Y., Miranda, R.N., Montes-Moreno, S.,
Dybkaer, K., Chiu, A., Orazi, A., Zu, Y., Bhagat,
G., Richards, K.L., Hsi, E.D., Choi, W.W., Zhao,
X., van Krieken, J.H., Huang, Q., Huh, J., Ai,
W., Ponzoni, M., Ferreri, A.J., Zhou, F., Slack,
G.W., Gascoyne, R.D., Tu, M., Variakojis, D.,
Chen, W., Go, R.S., Piris, M.A., Moller, M.B.,
Medeiros, L.J. & Young, K.H. (2013) MYC/BCL2
protein coexpression contributes to the inferior
survival of activated B-cell subtype of diffuse
large B-cell lymphoma and demonstrates high-
risk gene expression signatures: a report from
The International DLBCL Rituximab-CHOP
Consortium Program. Blood, 121, 4021–4031.
Hummel, M., Bentink, S., Berger, H., Klapper, W.,
Wessendorf, S., Barth, T.F., Bernd, H.W., Cogli-
atti, S.B., Dierlamm, J., Feller, A.C., Hansmann,
M.L., Haralambieva, E., Harder, L., Hasenclever,
D., Kuhn, M., Lenze, D., Lichter, P., Martin-
Subero, J.I., Moller, P., Muller-Hermelink, H.K.,
Ott, G., Parwaresch, R.M., Pott, C., Rosenwald,
A., Rosolowski, M., Schwaenen, C., Sturzen-
hofecker, B., Szczepanowski, M., Trautmann, H.,
Wacker, H.H., Spang, R., Loeffler, M., Trumper,
L., Stein, H. & Siebert, R. (2006) A biologic def-
inition of Burkitt’s lymphoma from transcrip-
tional and genomic profiling. N.Engl. Journal of
Medicine, 354, 2419–2430.
Jaffe, E., Harris, N., Stein, H. & Vardiman, J.W.
(2001) Pathology and genetics of tumours of
haematopoetic and lymphoid tissues. IARC
Press, Lyon, France.
Johnson, N.A., Savage, K.J., Ludkovski, O., Ben
Neriah, S., Woods, R., Steidl, C., Dyer, M.J., Sie-
bert, R., Kuruvilla, J., Klasa, R., Connors, J.M.,
Gascoyne, R.D. & Horsman, D.E. (2009) Lym-
phomas with concurrent BCL2 and MYC
translocations: the critical factors associated with
survival. Blood, 114, 2273–2279.
Johnson-Farley, N., Veliz, J., Bhagavathi, S. & Ber-
tino, J.R. (2015) ABT-199, a BH3 mimetic that
specifically targets Bcl-2, enhances the antitumor
activity of chemotherapy, bortezomib and JQ1 in
“double hit” lymphoma cells. Leukemia & lym-
phoma, 2015 Jan 28:1–7. [Epub ahead of print].
de Jong, D., Rosenwald, A., Chhanabhai, M.,
Gaulard, P., Klapper, W., Lee, A., Sander, B.,
Thorns, C., Campo, E., Molina, T., Norton, A.,
Hagenbeek, A., Horning, S., Lister, A., Rae-
maekers, J., Gascoyne, R.D., Salles, G. &
Weller, E. (2007) Immunohistochemical prog-
nostic markers in diffuse large B-cell lym-
phoma: validation of tissue microarray as a
prerequisite for broad clinical applications–a
study from the Lunenburg Lymphoma Biomar-
ker Consortium. Journal of Clinical Oncology,
25, 805–812.
Klapper, W., Szczepanowski, M., Burkhardt, B.,
Berger, H., Rosolowski, M., Bentink, S., Sch-
waenen, C., Wessendorf, S., Spang, R., Moller,
P., Hansmann, M.L., Bernd, H.W., Ott, G.,
Hummel, M., Stein, H., Loeffler, M., Trumper,
L., Zimmermann, M., Reiter, A. & Siebert, R.
(2008) Molecular profiling of pediatric mature
B-cell lymphoma treated in population-based
prospective clinical trials. Blood, 112, 1374–
1381.
Kluin, P. & Schuuring, E. (2011) Molecular cyto-
genetics of lymphoma: where do we stand in
2010? Histopathology, 58, 128–144.
Love, C., Sun, Z., Jima, D., Li, G., Zhang, J., Miles,
R., Richards, K.L., Dunphy, C.H., Choi, W.W.,
Srivastava, G., Lugar, P.L., Rizzieri, D.A., Lagoo,
A.S., Bernal-Mizrachi, L., Mann, K.P., Flowers,
C.R., Naresh, K.N., Evens, A.M., Chadburn, A.,
Gordon, L.I., Czader, M.B., Gill, J.I., Hsi, E.D.,
Greenough, A., Moffitt, A.B., McKinney, M.,
Banerjee, A., Grubor, V., Levy, S., Dunson, D.B.
& Dave, S.S. (2012) The genetic landscape of
mutations in Burkitt lymphoma. Nature Genet-
ics, 44, 1321–1325.
Masque-Soler, N., Szczepanowski, M., Kohler,
C.W., Spang, R. & Klapper, W. (2013) Molecu-
lar classification of mature aggressive B-cell lym-
phoma using digital multiplexed gene expression
on formalin-fixed paraffin-embedded biopsy
specimens. Blood, 122, 1985–1986.
Perry, A.M., Alvarado-Bernal, Y., Laurini, J.A.,
Smith, L.M., Slack, G.W., Tan, K.L., Sehn,
L.H., Fu, K., Aoun, P., Greiner, T.C., Chan,
W.C., Bierman, P.J., Bociek, R.G., Armitage,
J.O., Vose, J.M., Gascoyne, R.D. & Weisen-
burger, D.D. (2014) MYC and BCL2 protein
expression predicts survival in patients with dif-
fuse large B-cell lymphoma treated with ritux-
imab. British Journal of Haematology, 165, 382–
391.
Salaverria, I. & Siebert, R. (2011) The gray zone
between Burkitt’s lymphoma and diffuse large
B-cell lymphoma from a genetics perspective.
Journal of Clinical Oncology, 29, 1835–1843.
Siddiqui, W.A., Ahad, A. & Ahsan, H. (2015) The
mystery of BCL2 family: Bcl-2 proteins and
apoptosis: an update. Archives of Toxicology, 89,
289–317.
Swerdlow, S.H., Campo, E., Harris, N, Jaffe, E., Pi-
leri, S., Stein H, Thiele, J & Vardiman, JW
(2008) WHO Classification of Tumors of the
Haematopoietic and Lymphoid Tissues, IARC,
Lyon.
Ventura, R.A., Martin-Subero, J.I., Jones, M.,
McParland, J., Gesk, S., Mason, D.Y. & Siebert,
R. (2006) FISH analysis for the detection of lym-
phoma-associated chromosomal abnormalities in
routine paraffin-embedded tissue. The Journal of
molecular diagnostics : JMD, 8, 141–151.
Zhou, K., Xu, D., Cao, Y., Wang, J., Yang, Y. &
Huang, M. (2014) C-MYC aberrations as prog-
nostic factors in diffuse large B-cell lymphoma:
a meta-analysis of epidemiological studies. PLoS
ONE, 9, e95020.
N. Masque-Soler et al
8 ª 2015 John Wiley & Sons Ltd, British Journal of Haematology
